DNA methylation and incident cardiovascular disease

Area of Science:

• Epigenetics
• Cardiovascular Disease Research
• Biomarker Development

Background:

• DNA methylation is an epigenetic mark influenced by genetic and environmental factors.
• It holds potential as a biomarker for cardiovascular disease (CVD) risk.
• Standard association studies face challenges like reverse causation, limiting biomarker translation.

Purpose of the Study:

• To review recent investigations linking DNA methylation to incident CVD.
• To assess the potential of DNA methylation as a predictive biomarker for CVD risk.
• To explore causal inference in epigenomic associations with CVD.

Main Methods:

• Epigenome-wide association studies (EWAS) to identify loci with differential methylation before disease onset.
• Multivariate predictive modeling to assess DNA methylation's predictive power for CVD risk.
• Mendelian randomization studies to investigate the causality of epigenomic associations.

Main Results:

• EWAS have identified specific genetic loci with pre-disease methylation differences.
• Predictive modeling shows progress in utilizing DNA methylation for CVD risk assessment.
• Mendelian randomization provides insights into the causal relationships between methylation and CVD.

Conclusions:

• Recent studies enhance understanding of CVD pathophysiology through DNA methylation.
• This research supports the development of more reliable CVD risk biomarkers.
• DNA methylation is increasingly recognized for its role in CVD etiology and prediction.